Search Results
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Brendan J Nolan in
Google Scholar
PubMed
Search for other papers by Aviva S Frydman in
Google Scholar
PubMed
Search for other papers by Shalem Y Leemaqz in
Google Scholar
PubMed
Search for other papers by Meg Carroll in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Mathis Grossmann in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Jeffrey D Zajac in
Google Scholar
PubMed
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia
Search for other papers by Ada S Cheung in
Google Scholar
PubMed
Introduction Transgender (trans) individuals, including those who are binary and/or non-binary identified, undergoing feminising hormone therapy are often treated with oestradiol with or without anti-androgen therapy. Treatment allows the
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Hans Valdemar López Krabbe in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jørgen Holm Petersen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Department of Fertility, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for other papers by Louise Laub Asserhøj in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Trine Holm Johannsen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Peter Christiansen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Rikke Beck Jensen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Line Hartvig Cleemann in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Casper P Hagen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Lærke Priskorn in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Niels Jørgensen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Katharina M Main in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Lise Aksglaede in
Google Scholar
PubMed
; FSH, follicle-stimulating hormone; LH, luteinizing hormone; SDS, standard deviation score; total E2, total estradiol; TRT, testosterone replacement therapy. Anthropometric measurements and body composition in KS Patients with KS were
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Nathalie Ly in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
://doi.org/10.1016/j.fertnstert.2004.03.026 ) 16 Wirén L Boguszewski CL Johannsson G . Growth hormone (GH) replacement therapy in GH-deficient women during pregnancy . Clinical Endocrinology 2002 57 235 – 239 . ( https://doi.org/10.1046/j.1365
Search for other papers by Panagiotis Anagnostis in
Google Scholar
PubMed
Search for other papers by Irene Lambrinoudaki in
Google Scholar
PubMed
Search for other papers by John C Stevenson in
Google Scholar
PubMed
Search for other papers by Dimitrios G Goulis in
Google Scholar
PubMed
effect of menopausal hormone therapy (MHT) on this risk is also discussed. Does transition to menopause predispose to higher CVD risk? Menopause, defined as the completion of 12 months since the final menstrual period (FMP) or at the time of
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Search for other papers by Elinor Chelsom Vogt in
Google Scholar
PubMed
Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
Search for other papers by Francisco Gómez Real in
Google Scholar
PubMed
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Search for other papers by Eystein Sverre Husebye in
Google Scholar
PubMed
Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Sigridur Björnsdottir in
Google Scholar
PubMed
Department of Sleep, Landspitali University Hospital Reykjavík, Reykjavik, Iceland
Search for other papers by Bryndis Benediktsdottir in
Google Scholar
PubMed
Search for other papers by Randi Jacobsen Bertelsen in
Google Scholar
PubMed
Search for other papers by Pascal Demoly in
Google Scholar
PubMed
Search for other papers by Karl Anders Franklin in
Google Scholar
PubMed
Search for other papers by Leire Sainz de Aja Gallastegui in
Google Scholar
PubMed
Search for other papers by Francisco Javier Callejas González in
Google Scholar
PubMed
Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
Search for other papers by Joachim Heinrich in
Google Scholar
PubMed
Search for other papers by Mathias Holm in
Google Scholar
PubMed
Search for other papers by Nils Oscar Jogi in
Google Scholar
PubMed
Search for other papers by Benedicte Leynaert in
Google Scholar
PubMed
Search for other papers by Eva Lindberg in
Google Scholar
PubMed
Search for other papers by Andrei Malinovschi in
Google Scholar
PubMed
Albacete Faculty of Medicine, Castilla-La Mancha University, Albacete, Spain
Search for other papers by Jesús Martínez-Moratalla in
Google Scholar
PubMed
Search for other papers by Raúl Godoy Mayoral in
Google Scholar
PubMed
Search for other papers by Anna Oudin in
Google Scholar
PubMed
Search for other papers by Antonio Pereira-Vega in
Google Scholar
PubMed
Search for other papers by Chantal Raherison Semjen in
Google Scholar
PubMed
The National Research Center for the Working Environment, Copenhagen, Denmark
Search for other papers by Vivi Schlünssen in
Google Scholar
PubMed
Search for other papers by Kai Triebner in
Google Scholar
PubMed
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Search for other papers by Marianne Øksnes in
Google Scholar
PubMed
AS . Changes in body composition and weight during the menopause transition . JCI Insight 2019 4 e124865 . ( https://doi.org/10.1172/jci.insight.124865 ) 46 Waaseth M Bakken K Lund E . Patterns of hormone therapy use in the Norwegian Women
Search for other papers by Tristan Avril in
Google Scholar
PubMed
Search for other papers by Quentin Hennocq in
Google Scholar
PubMed
Search for other papers by Anne-Sophie Lambert in
Google Scholar
PubMed
Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France
Search for other papers by Juliane Leger in
Google Scholar
PubMed
Search for other papers by Dominique Simon in
Google Scholar
PubMed
Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France
Inserm UMR1185, Le Kremlin Bicetre, Paris, France
Search for other papers by Laetitia Martinerie in
Google Scholar
PubMed
Inserm UMR1185, Le Kremlin Bicetre, Paris, France
Paris-Saclay University, Paris, France
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
cryptorchidism ( 1 ). It can be isolated or part of a combined pituitary hormone deficiency (CPHD) ( 2 ) and is usually in relation to a dysfunction in gonadotropin-releasing hormone (GnRH) secretion or action. The major clinical consequences of CHH are pubertal
Molecular Reproductive Research Group, Department of Translational Medicine, Lund University, Malmö, Sweden
Institute of Molecular Biology and Biotechnology, FORTH, Heraklion, Greece
Search for other papers by Christos Tsatsanis in
Google Scholar
PubMed
Reproductive Medicine Centre, Skåne University Hospital Malmö, Malmö, Sweden
Search for other papers by Angel Elenkov in
Google Scholar
PubMed
Search for other papers by Irene Leijonhufvud in
Google Scholar
PubMed
Search for other papers by Katerina Vaporidi in
Google Scholar
PubMed
Search for other papers by Åsa Tivesten in
Google Scholar
PubMed
Reproductive Medicine Centre, Skåne University Hospital Malmö, Malmö, Sweden
Search for other papers by Aleksander Giwercman in
Google Scholar
PubMed
men (TM) on masculinizing hormone therapy receive gender-affirming hormone treatment with testosterone in the same dose regimens as CM with hypogonadism. Transgender women (TW) on feminizing hormone therapy receive androgen-depriving or blocking
Search for other papers by Lauren R Cirrincione in
Google Scholar
PubMed
Search for other papers by Bridgit O Crews in
Google Scholar
PubMed
Search for other papers by Jane A Dickerson in
Google Scholar
PubMed
Search for other papers by Matthew D Krasowski in
Google Scholar
PubMed
Search for other papers by Jessica Rongitsch in
Google Scholar
PubMed
Search for other papers by Katherine L Imborek in
Google Scholar
PubMed
CUNY Graduate School of Public Health and Health Policy, New York, New York, USA
Search for other papers by Zil Goldstein in
Google Scholar
PubMed
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA
Search for other papers by Dina N Greene in
Google Scholar
PubMed
Introduction Estradiol (17β-estradiol) is a natural sex steroid available in several exogenous preparations. The Endocrine Society recommended high-dose exogenous estradiol treatment as one part of feminizing hormone therapy for transgender
Search for other papers by Milou Cecilia Madsen in
Google Scholar
PubMed
Search for other papers by Martin den Heijer in
Google Scholar
PubMed
Search for other papers by Claudia Pees in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
Search for other papers by Leontine E H Bakker in
Google Scholar
PubMed
Haraldsen I Fisher AD Toye K Kaufman JM T’Sjoen G . Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence . Journal of Sexual
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Mette Bøgehave in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, Odense, Denmark
Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Jørgen Brodersen Gram in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Else-Marie Bladbjerg in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Marianne Skovsager Andersen in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Johannes Jakobsen Sidelmann in
Google Scholar
PubMed
Introduction Opioid medications are widely used to treat chronic non-cancer pain ( 1 ). Male hypogonadism, characterized by low concentrations of testosterone and luteinizing hormone (LH), is one of the most well-described hormonal adverse